Paclitaxel poliglumex a stellar performer in NSCLC

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1517, 2005-01, pp. : 9-10

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Paclitaxel poliglumex for ovarian cancer

By Galic Vijaya L   Wright Jason D   Lewin Sharyn N   Herzog Thomas J  

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 6, 2011-06 ,pp. : 813-821

Informa Healthcare

Access to resources Recommend Favorite

Paclitaxel poliglumex promising in heavily-pretreated ovarian cancer

By  

Inpharma, Vol. 1, Iss. 1467, 2004-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Paclitaxel/vinorelbine similar to paclitaxel/carboplatin in NSCLC

By  

Inpharma, Vol. 1, Iss. 1450, 2004-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Oxaliplatin plus paclitaxel in advanced NSCLC

By  

Inpharma, Vol. 1, Iss. 1444, 2004-01 ,pp. : 12-12

Adis International

Access to resources Recommend Favorite

Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC)

By Tran Hai   Zinner Ralph   Blumenschein George   Oh Yun   Papadimitrakopoulou Vassiliki   Kim Edward   Lu Charles   Malik Mubashira   Lum Bert   Herbst Roy  

Investigational New Drugs, Vol. 29, Iss. 3, 2011-06 ,pp. : 499-505

Springer Publishing Company

Access to resources Recommend Favorite